Using circular RNA to control any gene, in any species, in any cell type. "Acquired by Ginkgo Bioworks in 2022" Control of any Gene in any Species or Cell Type Circularis has used the power of circular RNA to develop a novel method to study and regulate gene expression. This technology has enabled increased bio-therapeutic production, improved targeting of gene therapy, and optimized expression in poorly studied organisms. The elegant design and high throughput nature of this technology enables breakthrough solutions without prior knowledge of the regulatory elements or coding sequence. Gene Expression, Bioprocessing, Molecular Biology, Protein Expression, Drug Discovery, …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unravelling complex biology with optogenetics, chemistry and computation for small molecule discovery. Our platform is built around a proprietary synthetic biology toolkit, featuring advanced optogenetic tools that enable precise temporal and spatial control of complex pathways and difficult-to-drug targets. Powered by vast proprietary datasets and cutting-edge AI models, our platform accelerates drug discovery and facilitates the generation of novel chemical matter, unlocking solutions for even the most challenging biological systems. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, small molecule, rejuvenation, molecular biology, and novel therapeutics

203 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Complete genes for complete cures Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them. Biotechnology, DNA therapeutics, Gene therapy, CRISPR, and Biological engineering

113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to cure genetic diseases At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

RNA Therapeutics We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

113 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology Data Analytics

Coave therapeutics Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success …

86 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

333 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Delivering the next generation gene therapies AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors Gene Therapy, Ophthalmology, and Rare diseases

338 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Seamless Therapeutics is overcoming the boundaries of gene editing by unlocking the full potential of recombinases. Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

44 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking access to genes with unparalleled accuracy Our mission is to enable synthetic biologists, by using our technology to unlock access to genes with unparalleled accuracy. We produce genes for a range of biotechnology customers including those in the pharmaceutical, agriculture and diagnostics sectors. Our technology offers access to long and complex gene sequences, which are normally difficult to produce. We are based in Cambridge UK, but we serve companies across the world. Camena's technology is positioned to enable researchers and the synthetic biology revolution. Twitter: @camenabio DNA synthesis, Complex genes, Synthetic Biology, synbio, and Gene synthesis

110 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP

279 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We turn blood stem cells into living drug factories At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

221 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the broad potential of RNA medicines to transform human health We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, …

67 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Precision Engineered Medicines to Silence Diseases Our 20-plus years of RNAi experience together with our validated mRNAi GOLDTM platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients …

50 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Engineering the future of RNAi-based medicines Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

On-target gene therapies Alia Therapeutics is a pioneering gene editing company with a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomic sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which are required for therapeutic applications.

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the next generation of mRNA medicines. At Sensible Biotechnologies, we are building best-in-class platform for manufacturing of high-quality mRNA in a scalable way to unlock the next generation of mRNA medicines and strengthen the global biosecurity.

109 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing

299 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Technology to ignite the biology revolution We are a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists'​ ability to use synthetic biology on a scale not currently possible. Biotechnology, Synthetic Biology, DNA synthesis, Gene synthesis, and synbio

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Outsmarting complex diseases with more intelligent medicines Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell …

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing our proprietary AxiomerTM RNA-editing platform technology Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary AxiomerTM RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/ RNA therapeutics, Drug development, Rare Diseases, Genetic Diseases, Orphan drugs, Pharmaceuticals, and RNA editing

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Genewity is a pioneering biotech start-up focused on advanced thymus-driven therapies for immune reconstitution. Supported by the extensive business expertise of our management and advisors, we are at the forefront of developing and commercialising breakthrough therapies. With over 150 years of combined experience in immunology and gene therapy, our team is uniquely positioned to drive advancements in the field.

275 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Follow Astellas Pharma for updates on our pipeline of genetic medicines for patients with rare diseases. The Astellas Gene Therapies page is no longer active or monitored. gene therapy and biotechnology

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Drugging disordered proteins with physics and AI Peptone is a therapeutics company that uses AI and an experimental physics product engine to design small molecules targeting the 6,200 intrinsically disordered human proteins that Alpha Fold 3 cannot model. artificial intelligence, structural biology, high performance computing, supercomputers, biotechnology, and intrinsically disordered proteins

142 similar entities Type: Startup Activities: biotech deeptech it services Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

213 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dare to Discover - Precision DNA & RNA services to accelerate cell, gene, and RNA therapies development. At Officinae Bio we're developing a platform to support the future of biologically designed therapeutics. By developing breakthroughs in AI-enabled methodologies for nucleic manufacture we’re supporting pioneering research in Gene-modified Cell therapy, Gene therapy and RNA therapeutic research. DNA platform An automated platform for streamlined development of plasmids and libraries for viral vector and mRNA. RNA platform Our industry leading mRNA development and manufacturing solutions support rapid turnaround, advanced transcription capabilities and precision control over regulatory sequences design. Artificial Intelligence, RNA synthesis, In …

43 similar entities Type: Startup Activities: manufacturing deeptech Technologies: A.I.

Edit the message. Rewrite the future. Pioneering RNA editing to deliver the future of medicine. Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

37 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology

88 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

The RNA Platform - by analyzing RNA we can detect disease, monitor health and design the Next Generation Cures Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression’s OneRNATM test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA’s to approved therapies and clinical trials. Genomics, information, personalized medicine, personalized diagnostics, Sequencing, prognostics, bioinformatics, sample preparation, Next Generation Sequencing, Biobank, Access to biological samples, target filtering, RNA-seq, RNA sequencing, and RNASeq of FFPE samples

102 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

An innovative gene editing company discovering and developing curative treatments for genetic diseases Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing …

82 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Developing a new class of ADCs based on NMT inhibition to treat cancer We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

226 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space. synthetic biology, RNA design, immunotherapy, covid-19, cancer, and mRNA therapy

108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ethris is paving a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform. Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

543 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease

160 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties. R&D-wise, GeneCode has remarkably improved the properties of the identified hits, making them more active and effective, drug-like and better show their ability to combat neurodegeneration in Parkinson ́s disease (PD).

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology